ADVERTISEMENT
Advertise

Content

List volumes - List articles in this issue

Short communication

Remission of Bullous Pemphigoid after Rituximab Treatment in a Psoriasis Patient on Regular Low-dose Methotrexate

doi: 10.2340/00015555-1619

Abstract:

Abstract is missing (Short)

Authors:

Ting-Shun Wang, Tsen-Fang Tsai
Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan

References

1. Bloom D. Psoriasis with superimposed bullous eruption. Med J Rec 1929; 130: 246.

2. Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63: 40–46.

3. Koerber WA, Price NM, Watson W. Coexistent psoriasis and bullous pemphigoid. A report of six cases. Arch Dermatol 1978; 114: 1643–1646.

4. Duong TA, Buffard V, André C, Ortonne N, Revuz J, Bagot M, et al. Efalizumab-induced bullous pemphigoid. J Am Acad Dermatol 2010; 62: 161–162.

5. Yasuda H, Tomita Y, Shibaki A, Hashimoto T. Two cases of subepidermal blistering disease with anti-p200 or 180-kD bullous pemphigoid antigen associated with psoriasis. Dermatology 2004; 209: 149–155.

6. Kawahara Y, Zillikens D, Yancey KB, Marinkovich MP, Nie Z, Hashimoto T, et al. Subepidermal blistering disease with autoantibodies against a novel dermal 200-kDa antigen. J Dermatol Sci 2000; 23: 93–102.

7. Nigam R, Levitt J. Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease? J Drugs Dermatol 2012; 11: 622–625.

8. Chang YS, Lee HT, Chen WS, Hsiao KH, Chen MH, Tsai CY, et al. Treatment of psoriasis with rituximab. J Am Acad Dermatol 2012; 66: e184–e185.

9. Jimenez-Boj E, Stamm TA, Sadlonova M, Rovensky J, Raffayová H, Leeb B, et al. Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis 2012; 71: 1868–1871.

10. Saraceno R, Citarella L, Spallone G, Chimenti S. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol 2007; 33: 154–155.

11. Olivieri I, D’Angelo S, Leccese P, Vertone D, Olivieri A. Worsening of psoriasis with rituximab therapy. Clin Exp Rheumatol 2010; 28: 926.

12. Guidelli GM, Fioravanti A, Rubegni P, Feci L. Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature. Rheumatol Int 2012 Nov 8. [E-pub ahead of print].

13. Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol 2012; 30: 78–83.

14. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011; 65: 552–558.

15. Van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2012 Nov 7. [E-pub ahead of print].

Related articles

There are no related articles.


Share with your friends





Actions


Abstract

Full text

PDF

Supplementary


There is no supplementary for this article.

Print information


Volume 94, Issue 1

DOI: 10.2340/00015555-1619

Pages: 108-109

View at PubMed